Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study

Autor: Burkhard Otremba, E. Nüesch, S Lauer, V. Misra, A Bouhlel, M. Shing, Elisabet Lidbrink, E Chmielowska, M. Liste Hermoso

Publikováno v: Breast Cancer Research and Treatment

Purpose Cardiac dysfunction risk associated with intravenous trastuzumab (H IV) treatment may differ in real-world practice versus randomized trials. We investigated cardiac events in patients with HER2-positive early breast cancer (EBC) treated with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::878f68e6bf02e52f1a4e150a4ddf0a05
https://doi.org/10.1007/s10549-018-5058-6

P30.07 Can Response to Chemotherapy Be a Surrogate of Response to Immunotherapy in Second and Subsequent Lines- Real World Data

Autor: A. Krause, E. Chmielowska, M. Olejniczak

Publikováno v: Journal of Thoracic Oncology. 16:S396-S397

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::788338731b7b5d9c38df38e5aa4a3a5e
https://doi.org/10.1016/j.jtho.2021.01.652

Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study

Autor: K. Bujko, L. Wyrwicz, A. Rutkowski, M. Malinowska, L. Pietrzak, J. Kryński, W. Michalski, J. Olędzki, J. Kuśnierz, L. Zając, M. Bednarczyk, M. Szczepkowski, W. Tarnowski, E. Kosakowska, J. Zwoliński, M. Winiarek, K. Wiśniowska, M. Partycki, K. Bęczkowska, W. Polkowski, R. Styliński, R. Wierzbicki, P. Bury, M. Jankiewicz, K. Paprota, M. Lewicka, B. Ciseł, M. Skórzewska, J. Mielko, M. Bębenek, A. Maciejczyk, B. Kapturkiewicz, A. Dybko, Ł. Hajac, A. Wojnar, T. Leśniak, J. Zygulska, D. Jantner, E. Chudyba, W. Zegarski, M. Las-Jankowska, M. Jankowski, L. Kołodziejski, A. Radkowski, U. Żelazowska-Omiotek, B. Czeremszyńska, L. Kępka, J. Kolb-Sielecki, Z. Toczko, Z. Fedorowicz, A. Dziki, A. Danek, G. Nawrocki, R. Sopyło, W. Markiewicz, P. Kędzierawski, J. Wydmański, J. Albiński, R. Banaś, E. Chmielowska, W. Bal, J. Baszczyk-Mnich, M. Bialas, T. Borowiec, M. Bujko, A. Cencelewicz, K. Chomik, M. Chwaliński, I. Ciepela, D. Dupla, A. Florek, A. Górnicki, K. Jeziorski, W. Józwicki, J. Kobiela, M. Koda, P. Kołodziej, P. Kruszewski, M. Kryj, G. Kuciel-Lisiecka, R. Kwiatkowski, A. Lachowski, P. Liszka-Dalecki, A. Majewski, W. Majewski, T. Majsak, D. Maka, M. Malka, A. Mazurkiewicz, J. Morawiec, E. Nogal, M. Olejniczak, D. Olkowski, K. Ostrowska-Cichocka, M. Pietruszka, G. Piotrkowski, M. Plewicka, D. Porzuczek-Zuziak, J. Reszke, A. Rychter, J. Sadowski, A. Salata, K. Serkies, E. Srutek, B. Szóstak, T. Tuziak, D. Tyralik, J. Skoczylas, E. Wachua, P. Wandzel, B. Winkler-Spytkowska, P. Wojtasik, K. Wroński, M. Zemal, I. Zygulski

Publikováno v: Annals of Oncology. 27:834-842

Background Improvements in local control are required when using preoperative chemoradiation for cT4 or advanced cT3 rectal cancer. There is therefore a need to explore more effective schedules. Patients and methods Patients with fixed cT3 or cT4 can

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d93be816279ca98185eb47994f8906e0
https://doi.org/10.1093/annonc/mdw062

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

Autor: Shannon Puhalla, M. Friedlander, Igor Bondarenko, Caroline Nickner, Qin Qin, Steven J. Isakoff, Paul K. Marcom, M. Campone, Erik Jakobsen, Judy Garber, E. Chmielowska, M Palácová, Christine K. Ratajczak, H.S. Han, William J. Gradishar, Melinda L. Telli, Mark E. Robson, Jane Qian, Agnes Jager, Susan M. Domchek, D Citrin, Virginia G. Kaklamani, Yaroslav Shparyk, Stacie Peacock Shepherd, Bella Kaufman, Véronique Diéras

Publikováno v: Annals of Oncology, 29(1), 154-161. Elsevier Ltd.
Han, H S, Diéras, V, Robson, M, Palácová, M, Marcom, P K, Jager, A, Bondarenko, I, Citrin, D, Campone, M, Telli, M L, Domchek, S M, Friedlander, M, Kaufman, B, Garber, J E, Shparyk, Y, Chmielowska, E, Jakobsen, E H, Kaklamani, V, Gradishar, W, Ratajczak, C K, Nickner, C, Qin, Q, Qian, J, Shepherd, S P, Isakoff, S J & Puhalla, S 2018, ' Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer : Randomized phase II study ', Annals of Oncology, vol. 29, no. 1, pp. 154-161 . https://doi.org/10.1093/annonc/mdx505

Background: Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase inhibitors, which interfere with DNA damage repair. Veliparib, a potent poly(ADP-ribose) polymerase inhibitor, enhanced the an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6245faf8fe340df6bb665b1a1db5b1a
https://pure.eur.nl/en/publications/f335467b-a340-4640-9706-dda834d92443